Clinical Trial

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Name: A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) — clinical trial record (NCT07701993)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NEBULA-1

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.

Trial Details

NCT Number	NCT07701993
Lead Sponsor	GlaxoSmithKline
Conditions	Metabolic Dysfunction-associated Steatohepatitis
Enrollment	1,740 participants
Start Date	2026-07-20
Primary Completion	2033-07-25 (estimated)
Study Completion	2033-08-22 (estimated)
Updated on ClinicalTrials.gov	2026-07-14